Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Antibodies against nuclear components (ANAs) occur in sera of approximately 50% of patients with primary biliary cirrhosis (PBC). By indirect immunofluorescence (IIF) ANA-positive PBC sera generate most frequently, homogeneous, speckled, centromere, and rim-like staining patterns. A perinuclear staining pattern is indicative for the reactivity of the sera with the components of the nuclear envelope. A substantial subset of PBC patients develops antibodies against constituents of the nuclear pore complexes (NPCs). These autoantibodies target two major autoantigens: gp210 glycoprotein and p62 kDa nucleoporin. Originally, a strong reaction of PBC with a 60 kDa protein of NPCs that was affinity purified on wheat-germ agglutinin (WGA)-Sepharose was described. Recently, using human recombinant p62 nucleoporin the identity of the reactivity was confirmed. In this work we compared by immunoprecipitation the reactivity of 20 PBC sera with the two recombinant autoantigens of the NPCs. Two out of 20 (10%) PBC sera precipitated recombinant gp210 glycoprotein and 11 out of 20 (55%) PBC sera reacted with p62 nucleoporin. These results evidence that anti-p62 antibodies occur more frequently than the autoantibodies against gp210 glycoprotein. Considering the recently reported clinical significance of ANAs in PBC, the prognostic value of the anti-NPC antibodies and their correlation with severity and progression of the disease is under evaluation.

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1398.058DOI Listing

Publication Analysis

Top Keywords

pbc sera
16
gp210 glycoprotein
12
components nuclear
8
nuclear pore
8
pore complexes
8
pbc
8
p62 nucleoporin
8
sera
6
antibodies
5
characterization autoantibodies
4

Similar Publications

Purpose Of Review: To synthesize current knowledge on the genetic, immunopathogenic, and clinical presentations of systemic sclerosis (SSc) and primary biliary cholangitis (PBC) with a focus on their co-occurrence as a clinically relevant overlap syndrome. This narrative review summarizes preclinical and clinical studies addressing SSc-PBC overlap.

Recent Findings: Genomic studies highlight shared susceptibility loci between SSc and PBC.

View Article and Find Full Text PDF

Background: Multiple myeloma (MM) is a common malignant tumor of the hematological system caused by the malignant proliferation of plasma cells, characterized by the production of M proteins and CRAB symptoms. Among them, the Immunoglobulin G MM is the most common, while the IgG4-MM is extremely rare. Smoldering multiple myeloma refers to a state where there are no clinical symptoms.

View Article and Find Full Text PDF

Definition and validation of recompensation in patients with primary biliary cholangitis-related decompensated cirrhosis treated with ursodeoxycholic acid: Based on the BAVENO VII criteria.

J Transl Int Med

August 2025

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University, Xi'an, Shaanxi Province, China.

Background And Objectives: Few studies have provided real-world data on the biochemical response, risk assessment, and prognosis of patients with primary biliary cholangitis (PBC)-related decompensated cirrhosis undergoing ursodeoxycholic acid therapy. The objective of this study is to define recompensation in this patient population based on the BAVENO VII criteria.

Methods: This retrospective analysis included 170 patients with cirrhosis who presented with ascites, hepatic encephalopathy, and/or variceal bleeding as their initial decompensating events at Xijing Hospital from 2006 to 2023.

View Article and Find Full Text PDF

Background And Aims: Primary biliary cholangitis (PBC) is an autoimmune liver disease that can progress to cirrhosis. However, reliable non-invasive tools for early cirrhosis risk stratification are still lacking. This study aimed to assess the diagnostic performance of fibroblast growth factor 19 (FGF19) in combination with the conventional liver fibrosis markers-aspartate aminotransferase-to-platelet ratio index(APRI), fibrosis-4 index(FIB-4), hyaluronic acid (HA), procollagen III N-terminal propeptide (PIIINP), collagen type IV (CIV), and laminin (LN) in PBC-associated cirrhosis.

View Article and Find Full Text PDF

Clinical significance of anti-mitochondrial antibodies and PBC-specific anti-nuclear antibodies in evaluating atypical primary biliary cholangitis with normal alkaline phosphatase levels.

Clin Chem Lab Med

August 2025

Department of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Clinical Teaching Hospital of Medical School, Nanjing University, Nanjing, China.

Objectives: The clinical implications of positive anti-mitochondrial antibodies (AMAs) and/or primary biliary cholangitis (PBC)-specific anti-nuclear antibodies (ANAs) in patients with normal alkaline phosphatase (ALP) remain uncertain.

Methods: Patients at The Second Hospital of Nanjing with positive AMAs/PBC-ANAs and normal ALP levels from January 2016 to July 2024 were categorized into three groups based on autoantibody profiles: [AMA/AMA-M2][gp210/sp100], [AMA/AMA-M2][gp210/sp100], and [AMA/AMA-M2][gp210/sp100]. The study compared PBC diagnostic rates, clinical symptoms, laboratory results, and pathology across these groups.

View Article and Find Full Text PDF